Administration, Sublingual

7 trials

Sponsors

National Center of Bioproducts (BIOCEN), Center for Genetic Engineering and Biotechnology (CIGB), in Havana, Center for Genetic Engineering and Biotechnology (CIGB)

Conditions

Acute Respiratory Infection (ARI) COVID-19 SARS-CoV2AsthmaAsthma.COVID-19 COVID-19 SARS-CoV2Contacts and SARS-CoV-2 infection suspects suspected of SARS-CoV-2 infectionPharmacodynamics and safety in healthy volunteers pharmacodynamicsimmunosenescence

Phase 1

Pharmacodynamics of the Nasalferon in healthy volunteers.

Active, not recruitingRPCEC00000308

Center for Genetic Engineering and Biotechnology (CIGB), in HavanaPharmacodynamics and safety in healthy volunteers pharmacodynamics

Start: 2020-05-04Target: 30Updated: 2026-03-30

Phase 2

Combined sublingual immunotherapy VALERGEN-DP and VALERGEN-BT-Asthma-Adults-Phase II

RecruitingRPCEC00000240

National Center of Bioproducts (BIOCEN)Asthma

Start: 2019-02-07Target: 120Updated: 2026-03-30

CIGB 2020 in contacts and SARS-CoV-2 infection suspects

RecruitingRPCEC00000306

Center for Genetic Engineering and Biotechnology (CIGB), in HavanaContacts and SARS-CoV-2 infection suspects suspected of SARS-CoV-2 infection

Start: 2020-03-27Target: 80Updated: 2026-03-30

Safety and immunogenicity of the CIGB 2020.

Active, not recruitingRPCEC00000326

Center for Genetic Engineering and Biotechnology (CIGB), in Havanaimmunosenescence

Start: 2020-07-29Target: 40Updated: 2026-03-30

Phase 3

Active, not recruitingRPCEC00000353

Center for Genetic Engineering and Biotechnology (CIGB), in HavanaCOVID-19 COVID-19 SARS-CoV2

Start: 2021-04-01Target: 354Updated: 2026-03-30

Phase 4

Pharmacovigilance-VALERGEN-Asthma

Active, not recruitingRPCEC00000231

National Center of Bioproducts (BIOCEN)Asthma.

Start: 2011-02-01Target: 2108Updated: 2026-03-30

Unknown Phase

CIGB2020- ARI elderly contacts

Active, not recruitingRPCEC00000356

Center for Genetic Engineering and Biotechnology (CIGB)Acute Respiratory Infection (ARI) COVID-19 SARS-CoV2

Start: 2021-03-12Target: 1440Updated: 2026-03-30

Related Papers

HeberNasvac, a Nasal and Sublingual Vaccine Formulation with Interferons Inducing Capacity

The American Journal of Public Health2025-12-30